Comfy Like An Old Pair Of Genes
Good morning, all ye Great Ones!
Sunday brunch time is upon us once again, and this time, I hope you brought your appetites for weird science.
Ugh, why is it always about food with you people?
Quiet, you. ‘Twas just a few weeks ago that we gorged ourselves on a hearty biotech breakfast — gene-editing giant Illumina Therapeutics (Nasdaq: ILMN) had just dropped one press release bombshell after another.
A partnership here to study genomics testing, a partnership there to test genetics-based drugs … Illumina’s DNA work is the stuff of science fiction, but it’s not alone. The biotech market never stops cooking up new weird science — lest of all the gene-editing gang.
And we’ve had one biotech breakfast, yes … but what about second breakfast?
Because fellow genomic guru Intellia (Nasdaq: NTLA) released some intel before the weekend, proving that Wall Street’s best and brightest biotechs are trying to get in everyone’s genes. (Hold up, I take that back.)
Longtime Great Ones know that Intellia develops genome-editing treatments that work inside the human body. Intellia also just announced it’s buying out Rewrite Therapeutics in a deal worth up to $200 million, greatly expanding the DNA-editing tech and research the company has at hand.
Neat facts, but … so what?
So what? Intellia is making groundbreaking strides for the cancer-testing industry … by literally editing and correcting the very building blocks of human beings. Are you not entertained?!
Plus, Rewrite is well-known for developing an approach that makes gene editing more efficient, meaning this isn’t the last time we’ll be touching on Intellia’s therapeutics — or the gene-editing market at large.
Keep your eyes peeled in these virtual pages for more DNA-based shenanigans — or click right here to see what’s going on in the genomics market right now!
Once you’ve checked that out, here’s some other Great Stuff you might’ve missed this week:
Hodl The Door!
Considering cashing in your crypto chips in light of recent market volatility? Here’s why hodling is actually your best bet.
Billionaires? Biotech? I’m Bemused.
Bezos and his billionaire buddies are all throwing their weight behind a new biotech trend called “Imperium.” Want to know why?
More Meta Than Meta
Ah yes, “smart glasses” … or, as I like to call it: “One more mark for Meta to miss.”
She Sells C Cells By The Seashore
Thanks to a brand-new battery tech that Charles Mizrahi calls “the forever battery,” coast-to-coast caravanning just got a whole lot easier for electric vehicle owners.
AT&T’s Dicey Discovery; Or, You Were Warnered
AT&T’s WarnerMedia spinoff is standard fare for Wall Street. But it’s more than just T’s dividend cut that disturbed investors.
Enjoy the rest of your weekend, Great Ones! We’ll be back with you tomorrow to … well … do it all over again.
In the meantime, write to us whenever the market muse calls to you! GreatStuffToday@BanyanHill.com is where you can reach us best.
And here’s where you can find our other junk — erm, I mean where you can check out some more Greatness:
- Get Stuff: Subscribe to Great Stuff right here!
- Our Socials: Facebook, Twitter and Instagram.
- Where We Live: GreatStuffToday.com.
- Our Inbox: GreatStuffToday@BanyanHill.com.
Until next time, stay Great!
